Market Place
Sourcing Support
NFL Bio: Patent Application Filed for Reducing Alcohol Consumption With Nfl-301
18 Jul 2023 //
GLOBENEWSWIRE
NFL Biosciences: Co-Founder Shareholder Further Strengthens His Position
05 Jul 2023 //
GLOBENEWSWIRE
NFL& GB HOLDING TAKES A STAKE IN THE COMPANYS CAPITAL UPON THE EXERCISE
29 Jun 2023 //
GLOBENEWSWIRE
Nfl Biosciences : Results Of The Combined General Meeting Of June 27, 2023
28 Jun 2023 //
GLOBENEWSWIRE
NFL BIOSCIENCES: Approval for its patent to be granted on NFL-101 in Europe
21 Jun 2023 //
GLOBENEWSWIRE
NFL Biosciences: Recruitment completed for the PRECESTO study
09 May 2023 //
GLOBENEWSWIRE
NFL Biosciences: 2022 full-year business and earnings update
25 Apr 2023 //
GLOBENEWSWIRE
NFL Biosciences : Activités & Résultats annuels 2022
25 Apr 2023 //
GLOBENEWSWIRE
Changes in the governance of NFL Biosciences
27 Feb 2023 //
GLOBENEWSWIRE
NFL BIOSCIENCES: Inclusion of the first volunteer in the PRECESTO study
22 Feb 2023 //
GLOBENEWSWIRE
NFL Biosciences receives 1.7 million in Avance Innovation funding from Bpifrance
20 Feb 2023 //
GLOBENEWSWIRE
NFL Biosciences collaborates with the CEA
02 Feb 2023 //
GLOBENEWSWIRE
Very successful capital increase for NFL Biosciences with over €3 million raised
31 Jan 2023 //
GLOBENEWSWIRE
NFL launches a round of fundraising for approximately 2.5 million euros
30 Jan 2023 //
GLOBENEWSWIRE
NFL Biosciences: CESTO II trial progressing on schedule
20 Jan 2023 //
GLOBENEWSWIRE
NFL Biosciences: Financial calendar for the first half of 2023
17 Jan 2023 //
GLOBENEWSWIRE
NFL Biosciences receives a joint grant from the French Gov for PRECESTO trial
11 Jan 2023 //
GLOBENEWSWIRE
NFL Biosciences -new patent application associating nfl-101 with other smoking cessation treatments
02 Nov 2022 //
GLOBENEWSWIRE
NFL BIOSCIENCES: NEW PATENT APPLICATION ASSOCIATING NFL-101 WITH OTHER SMOKING
01 Nov 2022 //
GLOBENEWSWIRE
NFL Biosciences: 2022 first-half business and earnings
25 Oct 2022 //
GLOBENEWSWIRE
NFL BIOSCIENCES PARTNERS WITH THEMIS MEDICARE FOR THE DEVP
05 Oct 2022 //
GLOBENEWSWIRE
NFL BIOSCIENCES HALF-YEAR REVIEW OF THE LIQUIDITY AGREEMENT FOR H1 2022
26 Jul 2022 //
GLOBENEWSWIRE
NFL Biosciences To Present At H.C.Wainwright Mental Health Conference
24 Jun 2022 //
GLOBENEWSWIRE
NFL BIOSCIENCES, which is committed to the fight against smoking
25 May 2022 //
GLOBENEWSWIRE
NFL BIOSCIENCES: Decision to approve the issuing of its patent in South Korea
11 May 2022 //
GLOBENEWSWIRE
NFL BIOSCIENCES: Notice of allowance of its patent in China
11 Apr 2022 //
GLOBENEWSWIRE
NFL Biosciences: 2021 full-year business and earnings update
28 Mar 2022 //
GLOBENEWSWIRE
Nfl Biosciences: Half-Year Review of the Liquidity Agreement for h2 2021
12 Jan 2022 //
GLOBENEWSWIRE
NFL Biosciences: Phase II/III clinical trial launched for smoking cessation
14 Dec 2021 //
GLOBENEWSWIRE
NFL BIOSCIENCES: agreement signed with Diverchim to manufacture
17 Nov 2021 //
GLOBENEWSWIRE
NFL BIOSCIENCES: Phase II/III clinical trial for NFL-101 for smoking cessation
16 Sep 2021 //
GLOBENEWSWIRE
